| Rank |
Status |
Study |
| 1 |
Unknown †
|
A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension
| Condition: |
Otitis Externa |
| Interventions: |
Drug: Cipro HC; Drug: Ciprofloxacin HCl and Hydrocortisone |
| Outcome Measures: |
Cure (reduced pain, swelling and otorrhea); Identification of possible side effects |
|
| 2 |
Recruiting
|
Ciprofloxacin for Prevention of BK Infection
| Condition: |
BK Virus Infection |
| Interventions: |
Drug: Ciprofloxacin; Drug: placebo |
| Outcome Measures: |
BK infection at 6 months post-transplant; Incidence of urinary tract infections as defined by a midstream urine sample containing 10^4 or more colony-forming units per mL; Incidence of bacteremic infections at 6 months. Incidence of bacteremia as defined by a single positive blood culture that was not thought to be contaminated.; Incidence of quinolone-resistant bacterial infections; Incidence of clostridium difficile infection; Serious adverse events; Time to BK infection; Proportion of patients developing BK infection at 1 year; First and peak plasma viral loads; Incidence of acute rejection at 1 year; Incidence and severity of BK nephropathy, as defined by positive staining of histopathological specimen, at 1 year |
|
| 3 |
Recruiting
|
Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
| Condition: |
Bronchiectasis |
| Interventions: |
Drug: Ciprofloxacin: administered for 28 days on / 28 days off; Drug: Placebo: administered for 28 days on / 28 days off; Drug: Ciprofloxacin: administered for 14 days on / 14 days off; Drug: Placebo: administered for 14 days on / 14 days off |
| Outcome Measures: |
Time to first exacerbation; Mean number of exacerbations per patient per 48 weeks; Pathogens present at baseline and eradicated at 48 weeks; Quality of Life: Changes of Saint George's Respiratory; New pathogens at 48 weeks, not present at baseline; Changes of Forced Expiratory Volume in 1 second from baseline; Number of participants with Adverse events as a measure of |
|
| 4 |
Recruiting
|
Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy Tubes
| Condition: |
Otitis Media in Patients With Tympanostomy Tubes. |
| Interventions: |
Drug: Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension; Drug: CiproDEX® (Ciprofloxacin 0.3%/dexamethasone 0.1%); Drug: Placebo Sterile Otic Suspension |
| Outcome Measures: |
Clinical Success; Cessation of Otorrhea |
|
| 5 |
Recruiting
|
Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention
| Condition: |
Adverse Reaction to Other Drugs and Medicines |
| Interventions: |
Drug: Norfloxacin; Drug: Ciprofloxacin |
| Outcome Measures: |
The prevention rate of spontaneous bacterial peritonitis (SBP); 1 year mortality; Incidence of infectious event other than SBP; Hepatorenal syndrome; Hepatic encephalopathy; Adverse event of drugs |
|
| 6 |
Unknown †
|
TINN Pharmacokinetics (PK) Study Treat Infections iN Neonates
| Condition: |
Pharmacokinetics of Ciprofloxacin in Neonates |
| Intervention: |
Procedure: Collection of biological samples |
| Outcome Measures: |
Ciprofloxacin plasma concentration and population pharmacokinetic (PK) parameters; PK variables; Tolerability; Safety; Clinical/microbiological outcomes |
|
| 7 |
Recruiting
|
Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
| Condition: |
Bronchiectasis |
| Interventions: |
Drug: Ciprofloxacin DPI (BAYQ3939); Drug: Placebo |
| Outcome Measures: |
Time to first exacerbation; Mean number of exacerbations per patient per 48 weeks; Pathogens present at baseline and eradicated at 48 weeks; Changes of Saint George's Respiratory Questionnaire score from baseline to 48 weeks; New pathogens at 48 weeks, not present at baseline; Changes of Forced expiratory volume in 1 second from baseline to 48 weeks; Number of participants with Adverse events as a measure of safety and tolerability |
|
| 8 |
Recruiting
|
A Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin in the Treatment of Plague in Humans
| Condition: |
Plague |
| Interventions: |
Drug: Ciprofloxacin; Drug: doxyxcycline |
| Outcome Measures: |
all cause mortality; time to defervesence; antimicrobial associated adverse events |
|
| 9 |
Not yet recruiting
|
Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects
| Conditions: |
Healthy Volunteers; Non-smokers |
| Interventions: |
Drug: Pracinostat; Drug: Itraconazole; Drug: Ciprofloxacin |
| Outcome Measures: |
Peak plasma concentration Cmax in healthy nonsmoking subjects given a single-dose of pracinostat; Number of participants with Adverse Events as a measure of safety and tolerability of single-dose pracinostat when administered with itraconazole or with Ciprofloxacin in healthy nonsmoking adult subjects.; Peak plasma PK concentration Area Under the Curve (AUC)AUC 0-t, AUC 0-inf in healthy nonsmoking subjects given a single dose of pracinostat |
|
| 10 |
Recruiting
|
Population Pharmacokinetics of Anti-infectious Drugs in Children
| Conditions: |
Pediatrics; Ceftazidime; Ciprofloxacin; Voriconazole |
| Interventions: |
Drug: Ceftazidime; Drug: Ciprofloxacin; Drug: Voriconazole |
| Outcome Measures: |
Population pharmacokinetic parameters and factors explaining variability; Covariability factors explaining the variability (age, biological data, pharmacokinetics factors, associated treatments...) |
|
| 11 |
Recruiting
|
A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis Externa
| Condition: |
Otitis Externa |
| Interventions: |
Drug: Ciprofloxacin/Dexamethasone; Drug: Ciprodex (R); Drug: Placebo |
| Outcome Measures: |
Clinical Success; Resolution of Symptoms |
|
| 12 |
Recruiting
|
Efficacy Study of Prophylaxis With Fosfomycin Versus Ciprofloxacin Prior Prostate Biopsy
| Condition: |
Urinary Tract Infections |
| Interventions: |
Drug: Fosfomycin 3 g; Drug: Ciprofloxacin 500 mg |
| Outcome Measures: |
Bacteriuria; Urinary Tract Infection; Sepsis; Pathogens present in urine and antimicrobial resistance; Bacteremia; Hematuria; Hemospermia; Rectal bleeding; Urinary retention; Difficulty for miction; Genitourinary infections associated to fever (>38ºC); Number of participants with adverse events |
|
| 13 |
Recruiting
|
BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent
| Conditions: |
HIV; Salivary Gland Disease; Benign Lymphoepithelial Lesion |
| Interventions: |
Drug: Ciprofloxacin; Drug: Placebo |
| Outcome Measures: |
(BK) Virus replication and shedding; Salivary function |
|
| 14 |
Recruiting
|
Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis
| Conditions: |
Urinary Tract Infections; Acute Pyelonephritis |
| Interventions: |
Drug: Finafloxacin 800 mg i.v. once daily; Drug: Finafloxacin placebo i.v. once daily; Drug: Finafloxacin 800 mg tablets (as four 200 mg tablets) once daily; Drug: Finafloxacin placebo tablets (as four tablets) once daily; Drug: Ciprofloxacin 400 mg i.v. two times daily; Drug: Ciprofloxacin placebo i.v. two times daily; Drug: Ciprofloxacin 500 mg oral (as two 250 mg capsules) two times daily; Drug: Ciprofloxacin placebo oral (as two capsules each) two times daily |
| Outcome Measures: |
Clinical and microbiological response of patients with cUTI or pyelonephritis.; The clinical and microbiological response at the On Therapy (OT) visit (Day 3).; The clinical and microbiological response at the End of Therapy (EoT) visit (Day 10).; The clinical and microbiological response at the End of Study (EoS) visit (Day 24).; The safety and tolerability of multiple doses of finafloxacin of both 5 days and 10 days of treatment with finafloxacin (i.v. and oral) in subjects with cUTI, compared to 10 days of Ciprofloxacin (i.v. and oral).; The predictive capacity of PK/PD data of both 5 days and 10 days of treatment with finafloxacin (i.v. and oral) in subjects with cUTI, using 10 days of Ciprofloxacin (i.v. and oral) as reference on clinical outcomes (EMA guidance). |
|
| 15 |
Recruiting
|
Antibiotic Prophylaxis for Transrectal Prostate Biopsy
| Condition: |
Infection |
| Interventions: |
Drug: Ciprofloxacin; Drug: trimethoprim-sulfamethoxazole; Drug: cefuroxime; Drug: ceftriaxone; Drug: gentamicin; Drug: amikacin; Drug: aztreonam; Drug: imipenem |
| Outcome Measures: |
Infection rates; Infection rate; Demographics and medical co-morbidities; Genus and species of rectal swab isolates with their antibiotic susceptibility profiles |
|
| 16 |
Recruiting
|
Phase 3 Study With Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis
| Condition: |
Non Cystic Fibrosis Bronchiectasis |
| Intervention: |
Drug: Ciprofloxacin |
| Outcome Measures: |
Time to first exacerbation; Number of exacerbations |
|
| 17 |
Recruiting
|
A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia
| Condition: |
Pneumonia |
| Intervention: |
Drug: Ciprofloxacin (Cipro, BAYQ3939) |
| Outcome Measures: |
Safety variables will be summarized using descriptive statistics based on adverse events collection; AUC (Area under the blood concentration/time curve); Cmax (Maximum observed concentration); AUC/MIC (Minimum inhibitory concentration); Cmax/MIC; AUC/MPC (Mutant prevention concentration); Cmax/MPC; Clinical response rate based on resolution of signs and symptoms; Microbiological response rate, assessed as eradication rate based on microbiologically evaluable patients; Test of cure rate based on resolution of signs, symptoms, and the clinical response |
|
| 18 |
Recruiting
|
Antibiotics and Hydroxychloroquine in Crohn's
| Condition: |
Crohn's Disease |
| Interventions: |
Drug: Ciprofloxacin; Drug: Doxycycline; Drug: Hydroxychloroquine; Drug: Budesonide |
| Outcome Measures: |
• Remission, defined as Crohn's Disease activity index (CDAI) <150 at 10 weeks without addition of any other medication or treatment for the Crohn's Disease.; • Remission, defined as CDAI ≤150 maintained through to 24 weeks; • Remission, defined as CDAI ≤150 maintained through to 52 weeks; • Remission defined as CDAI <150 at 4 weeks; • Response defined as a fall in CDAI by >70 points at 4 weeks and 10 weeks; • Markers of cost (days admitted to hospital, days unable to carry out normal daily activities, need for surgery); • Quality of life at 4 weeks, at 10 weeks, or Early Withdrawal; • Patient global assessment of symptom severity by 10 cm visual analogue score at 4 weeks, at 10 weeks, or Early Withdrawal; • Adverse Events and possible drug-related side effects: nausea, diarrhoea, mood disturbance, sleep disturbance - will all be assessed at each visit; • Fall in Faecal Calprotectin |
|
| 19 |
Recruiting
|
A Pilot Study on the Use of Prophylactic Antibiotics for EUS-guided Pancreatic Cyst Aspiration
| Condition: |
Pancreatic Cysts |
| Interventions: |
Drug: Ciprofloxacin; Other: Placebo (for Ciprofloxacin) |
| Outcome Measures: |
Number of patients with pancreas cyst infection after EUS-guided pancreatic cyst aspiration; Secondary outcomes; secondary outcome |
|
| 20 |
Unknown †
|
Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases
| Condition: |
Febrile Neutropenia |
| Interventions: |
Drug: Ciprofloxacin; Drug: cefepime |
| Outcome Measures: |
Treatment efficacy; Toxicity |
|
